Amlodipine/atorvastatin/valsartanAlternative Names: CJ-30061
Latest Information Update: 24 Dec 2015
At a glance
- Originator CJ HealthCare
- Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists; HMG-CoA reductase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Hyperlipidaemia; Hypertension
Most Recent Events
- 24 Dec 2015 Phase-I clinical trials in Hypertension in South Korea (PO) prior to December 2015 (CJ Healthcare pipeline, December 2015)
- 24 Dec 2015 Phase-I clinical trials in Hyperlipidaemia in South Korea (PO) prior to December 2015 (CJ Healthcare pipeline, December 2015)